A novel inhibitor of ADAM-17, ZLDI-8, suppresses hepatocellular carcinoma metastasis both in vitro and in vivo by reversing the process of epithelial-mesenchymal transition (19). Here, ADAM17 is linked to hepatocellular carcinoma.